eliquis apixaban logo eliquis apixaban logo eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Choose ELIQUIS (apixaban) for your patients with NVAF

ELIQUIS – AN ORAL, DIRECT FACTOR XA INHIBITOR – IS INDICATED FOR:

  • Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure
    (NYHA class ≥II).1

When efficacy and safety profiles matter, choose ELIQUIS

Explore data for ELIQUIS in NVAF

For both of us, efficacy and safety profiles matter

In patients with NVAF, ELIQUIS is the only factor Xa inhibitor to demonstrate:

  • Superiority on stroke / systemic embolism vs. warfarin2
  • Superiority on major bleeding vs. warfarin2

Explore data for ELIQUIS in NVAF

ARISTOTLE clinical trial

ELIQUIS has been compared with warfarin in a Phase III trial for the prevention of stroke / systemic embolism in patients with NVAF.2

 ELIQUIS demonstrated superior risk reduction in stroke / systemic embolism with significantly less major bleeding vs. warfarin in patients with NVAF.2

Learn more about the ARISTOTLE trial.

AVERROES clinical trial

ELIQUIS is the only NOAC to be compared with a pre-specified aspirin treatment arm in a Phase III trial in patients with NVAF considered unsuitable for warfarin.3

Learn more about the AVERROES trial.

Real-world data

Favourable efficacy and major bleeding outcomes vs. warfarin, demonstrated in randomised controlled trials,1 are now reflected by real-world experience in the USA.4

Learn more about ELIQUIS real world data.

Help protect your patients with NVAF against stroke / systemic embolism

ELIQUIS 5 mg BD: simple dosing for stroke prevention in NVAF, with or without food

It’s simple to switch your patients to ELIQUIS1

View information to assist your daily practice, including adverse reactions, contraindications and interactions


ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

ARISTOTLE = Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation   
AVERROES = Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment   
BD = Twice Daily   
NOAC = Non-vitamin K antagonist Oral Anticoagulant   
NVAF = Non-Valvular Atrial Fibrillation   
NYHA = New York Heart Association   
TIA = Transient Ischaemic Attack

References

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. Granger CB et al. N Engl J Med 2011; 365: 981–992.
  3. Connolly SJ et al. N Engl J Med 2011; 364: 806–817.
  4. Yao X et al. J Am Heart Assoc 2016; 5: e003725.